Holen Sie sich die Stockscreener-App
31.75
4.68%
1.42
Viridian Therapeutics Inc Aktie (VRDN) Neueste Nachrichten
Will Viridian Therapeutics Inc. stock continue upward momentumJuly 2025 Decliners & Real-Time Buy Zone Alerts - ulpravda.ru
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 8, 2026 - BioSpace
Is Viridian Therapeutics Inc. stock attractive after correctionCPI Data & Technical Entry and Exit Alerts - ulpravda.ru
How Viridian Therapeutics Inc. stock compares to market leaders2025 Trading Volume Trends & Expert Approved Momentum Ideas - ulpravda.ru
Why CHRO stock attracts strong analyst attention - ulpravda.ru
Can Viridian Therapeutics Inc. stock deliver strong Q4 earningsQuarterly Market Review & Real-Time Chart Pattern Alerts - ulpravda.ru
VRDN: Truist Securities Lowers Price Target but Maintains Buy Ra - GuruFocus
Why Viridian Therapeutics Inc. stock is in analyst buy zonePortfolio Gains Report & Smart Investment Allocation Insights - ulpravda.ru
UBS Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - Nasdaq
Will Viridian Therapeutics Inc. stock deliver consistent dividendsLong-Term Growth Stocks & Turn Market Volatility into Wealth - ulpravda.ru
VRDN: UBS Initiates Coverage with a 'Buy' Rating and $50 Price Target | VRDN Stock News - GuruFocus
Why Viridian Therapeutics Inc. stock remains resilientHigh Beta Stocks & Outstanding Portfolio Tips - ulpravda.ru
UBS initiates Viridian Therapeutic stock with Buy rating on TED treatment - Investing.com Canada
Jefferies reiterates Buy rating on Viridian Therapeutic stock with $44 target - Investing.com Canada
Viridian Therapeutic stock a Top Pick at TD Cowen ahead of busy 2026 - Investing.com Canada
Viridian Therapeutics Prepares for Transformational 2026 - BioSpace
Viridian Therapeutics, Inc. (VRDN) Investor Outlook: Exploring a Potential 36.59% Upside in the Biotech Arena - DirectorsTalk Interviews
Entry Recap: Will Viridian Therapeutics Inc. stock outperform international peersMarket Volume Report & Consistent Profit Trading Strategies - ulpravda.ru
Understanding the Setup: (VRDN) and Scalable Risk - Stock Traders Daily
Viridian Therapeutics (NASDAQ:VRDN) Insider Sells $70,795.52 in Stock - MarketBeat
Insider Sell: Jennifer Tousignant Sells 2,272 Shares of Viridian Therapeutics Inc (VRDN) - GuruFocus
Viridian Therapeutics (VRDN) Chief Legal Officer reports 2,272-share stock sale - Stock Titan
What to keep an eye on in 2026 - Eyes On Eyecare
What analysts say about Viridian Therapeutics Inc stockGrowth vs. Value Investing & Low Risk Investment Tips - earlytimes.in
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Benzinga
Viridian Therapeutics Earnings Notes - Trefis
Simplify Asset Management Inc. Purchases Shares of 50,000 Viridian Therapeutics, Inc. $VRDN - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Market Fear: How Viridian Therapeutics Inc 1S1 stock performs during market turbulenceJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Rice Hall James & Associates LLC Purchases 336,040 Shares of Viridian Therapeutics, Inc. $VRDN - MarketBeat
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN), MDxHealth (MDXH) and RxSight (RXST) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Viridian Therapeutics (VRDN), Fortrea Holdings Inc. (FTRE) and Cytokinetics (CYTK) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (VRDN) and Sanofi (OtherSNYNF) - The Globe and Mail
VRDN: Needham Maintains Buy Rating and Raises Price Target | VRD - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $42.00 at Needham & Company LLC - MarketBeat
Viridian Therapeutics, Inc. (VRDN) Stock Analysis: Unlocking a 27% Potential Upside in Biotech - DirectorsTalk Interviews
Viridian Therapeutics: De-Risked Veligrotug Program and Compelling Phase III Data Support Undervalued Buy Rating - TipRanks
Viridian Therapeutics Says FDA Accepts Biologics License Application for Veligrotug - marketscreener.com
Viridian Therapeutics (VRDN) Gains FDA Priority Review for Thyro - GuruFocus
FDA grants priority review for Viridian’s thyroid eye disease drug - Investing.com
Viridian Therapeutics announces BLA acceptance and Priority Review for Veligrotug for the treatment of thyroid eye disease - marketscreener.com
Viridian Therapeutics Announces BLA Acceptance And Priority Review For Veligrotug For The Treatment Of Thyroid Eye Disease - TradingView — Track All Markets
Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease - Business Wire
Will Viridian Therapeutics Inc. stock attract more institutional investorsJuly 2025 Retail & High Win Rate Trade Tips - Улправда
Published on: 2025-12-20 23:42:03 - Улправда
FDA Review Of Veli For Thyroid Eye Disease Might Change The Case For Investing In Viridian Therapeutics (VRDN) - Sahm
Aug Action: How geopolitical tensions affect Viridian Therapeutics Inc. stock2025 Support & Resistance & Community Verified Trade Signals - Улправда
Why Viridian Therapeutics Inc. (1S1) stock gets analyst attentionMarket Trend Summary & Weekly Breakout Watchlists - DonanımHaber
Published on: 2025-12-19 16:37:51 - Улправда
Evercore ISI Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN) - The Globe and Mail
Fed Watch: Will Viridian Therapeutics Inc. stock attract more institutional investorsPortfolio Update Report & AI Powered Buy and Sell Recommendations - Улправда
Goldman Sachs reiterates Buy rating on Viridian Therapeutic stock By Investing.com - Investing.com Canada
Will Viridian Therapeutics Inc. stock outperform international peers2025 Winners & Losers & Low Risk High Reward Ideas - Улправда
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Viridian Therapeutics (VRDN) and OmniAb (OABI) - The Globe and Mail
Viridian Therapeutics stock reaches 52-week high at 33.67 USD By Investing.com - Investing.com Australia
Viridian Therapeutics stock reaches 52-week high at 33.67 USD - Investing.com India
Viridian Therapeutics, Inc. (VRDN) Stock Surges on Dec. 15, 2025: Latest News, Analyst Forecasts, and 2026 Catalysts - ts2.tech
Viridian Therapeutics (VRDN) Sees 5% Stock Increase - GuruFocus
Argenx (ARGX) Ends Study of Efgartigimod for Thyroid Eye Disease - GuruFocus
Viridian Therapeutics (NASDAQ:VRDN) Sets New 52-Week HighShould You Buy? - MarketBeat
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):